The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

I've been writing about the LG C3 OLED TV since its release in 2023, and it has consistently been a best-seller, thanks to ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

The stock rallies as C3.ai touts enterprise AI momentum, but rising pressure from rivals puts its niche to the test.

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

This leader in cloud observability is swiftly moving into the artificial intelligence space, and it's having major success.

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.